ProteLight Medical Holdings (Hong Kong) Co., Ltd. (hereinafter referred to as "ProteLight Hong Kong") was registered in the Hong Kong Region. It is a wholly-owned subsidiary of Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.  (hereinafter referred to as "Jiangsu ProteLight) and was established in 2021 January. ProteLight Hong Kong is an important platform and window for Jiangsu ProteLight’s international development strategy. It is mainly responsible for the first-in-class innovative drugs such as antimicrobial peptides and anti-cancer peptides from Jiangsu ProteLight researching and developing in countries and regions outside mainland China; the organization of drug R&D and clinical research trials; and the operation and management of innovative drugs in the international market. ProteLight Hong Kong commits to applying the first-in-class innovative drugs such as antimicrobial peptides and anticancer peptides to help the international community solve world-wide problems such as drug-resistant bacterial infections and tumors; and contributes to protecting human health.